Welcome to the Journal of Immunological Sciences

Manuscript Guidelines

The journal has specific rules to formatting a manuscript that authors should adhere to before shipping their manuscript. These guidelines are primarily intended to make the submission of manuscript quick and easy.    Read More

click here

Ethics & Disclosures

Journal of Immunological Sciences is primarily based on values centered on loyalty, commitment, scientific accuracy, and ethics. It has adopted clear and rigorous ethical guidelines for best working practices.    Read More

What happens next to your Submission

Each article we publish benefits from hundreds of hours of work by Chief editors, Sectional editors, Reviewers, Manuscript editors, Proofreaders, Graphics and Web experts, who work to ensure that the manuscript meets our standards.    Read More

cover-image

Focus & Scope


Journal of Immunological Sciences is a multidisciplinary, open access, peer reviewed, non-profit journal, that publishes papers of the highest quality and significance in all areas of immunology. It aims at playing an essential role in monitoring advances in the various fields of immunology, bringing together the results in a readable and lucid form. It publishes high-impact, cutting-edge research papers for immunologists, physicians and researchers interested in immunology. It provides a novel way to disseminate the latest findings in basic and translational research in Immunology and to facilitate communication, both among scientists as well as the community at large.

The Journal of Immunological Sciences welcomes submissions that explore novel ideas and approaches, as long as they are underpinned by conventional scientific practice and present falsifiable hypothesis that are tested with empirical methods and evidences.

This journal publishes research articles relevant to (but not limited) immune system and its molecular, functional, histological, developmental, cellular aspects.

Read more

e-Submission

Recent Articles


Vol 3-2 Mini Review

The Neuro-Psychological Axis of Smoking-Associated Cancer

Hildegard M Schuller*

Department of Biomedical & Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, 2407 River Drive, Knoxville, TN 37996, USA

This mini-review summarizes current knowledge on similarities and synergism between smoking and psychological stress-induced modulations of growth stimulating and inhibiting regulatory networks in epithelial cells and epithelial cancers with emphasis on cancer stimulating neurotransmitters and their receptors as well as cancer inhibiting γ-aminobutyric acid (GABA) and opioids. Hyperactive cAMP signaling downstream of beta-adrenergic receptors (β-ARs) has been identified as the driving force of most smoking-associated cancers by numerous preclinical studies and psychological stress intensifies these effects while experimental stress reduction inhibits. The integration of cAMP reduction via stress reduction by pharmacological and psychological means such as psychotherapy, relaxation meditation and yoga into any cancer treatment strategy is recommended.

DOI: 10.29245/2578-3009/2019/2.1166 View / Download Pdf View Full Text
Vol 3-2 Research Article

Time from Stereotactic Radiotherapy to Immunotherapy Is a Predictor for Outcome in Stage IV Non-Small Cell Lung Cancer

Rodney E. Wegner1*, Stephen Abel1, Shaakir Hasan1, Richard J. White1, Gene Finley2, Dulabh Monga2, Athanasios Colonias1, Vivek Verma1

1Allegheny Health Network Cancer Institute, Division of Radiation Oncology, USA

2Allegheny Health Network Cancer Institute, Division of Medical Oncology, USA

Immunotherapy (IMT) has revolutionized the treatment of stage IV non-small cell lung cancer (NSCLC). However, optimal timing of IMT in relation to stereotactic radiosurgery (SRS) or stereotactic body radiotherapy (SBRT) is unknown. Utilizing the National Cancer Database, we examined trends in IMT use in metastatic NSCLC patients and the potential survival implications of IMT timing in relation to SBRT/SRS. We queried the NCDB for patients with Stage IV NSCLC diagnosed between 2004-2015. Patients receiving IMT and SBRT/SRS to any site were included. Multivariate logistic regression identified predictors of IMT use. Receiver operator characteristic curve analysis determined an a priori timeframe between SBRT and IMT predictive of optimal overall survival (OS). Univariate and multivariate analyses identified factors predictive of OS. Propensity-adjusted Cox proportional hazard ratios were used to mitigate indication bias. Of 13,862 eligible patients, 371 received IMT. The majority (75%) received chemotherapy. IMT use was associated with improved median OS on univariate analysis (17 vs. 13 months, p<0.0001). Adenocarcinoma histology, chemotherapy use, and recent treatment year were associated with IMT. On multivariate propensity-adjusted Cox regression, predictors for improved OS included: younger age, lower comorbidity score, lower grade, private insurance, IMT use, and female sex. Patients treated ≥ 21 days (a priori threshold) after SBRT/SRS initiation had improved median OS (19 vs. 15 months, p=0.0335). In patients with Stage IV NSCLC, IMT use following SBRT/SRS has increased. OS improved when IMT was given ≥3 weeks after initiating SBRT/SRS; suggesting a potential optimal time-frame between RT and IMT.

DOI: 10.29245/2578-3009/2019/2.1171 View / Download Pdf View Full Text
Vol 3-2 Mini Review

Detection of Antigen-Specific T Cell Lineages and Effector Functions Based on Secretory Signature

Greg A. Kirchenbaum, Jodi Hanson, Diana R. Roen, Paul V. Lehmann*

Cellular Technology Limited (CTL) Shaker Heights, OH, 44122-5350, USA

T cells not only protect us from infectious diseases and cancer, but are also involved in transplant rejection, autoimmune diseases, and allergies. Each of these immunologic processes share a common link in which antigen-specific T cells undergo expansion, with some of the resulting progeny differentiating into memory cells. Memory T cells belong to several distinct lineages, and sub-lineages, that fundamentally differ in their effector functions and capacity to mediate a protective or pathological immune response. In this mini-review, we outline how such memory T cell subpopulations can readily be identified on the basis of their secretory signature using a multi-color ImmunoSpot® assay.

DOI: 10.29245/2578-3009/2019/2.1168 View / Download Pdf View Full Text
Vol 3-2 Research Article

National Trends in the Use of Targeted Therapy and Immunotherapy in the Up Front Management of Glioblastoma

Richard White1, Stephen Abel2, Shaakir Hasan2, Vivek Verma2, Tulika Ranjan3, Stephen M. Karlovits2, Rodney E Wegner2*

1Allegheny Health Network, Department of Internal Medicine, Pittsburgh, PA, USA

2Allegheny Health Network Cancer Institute, Division of Radiation Oncology, Pittsburgh, PA, USA

3Allegheny Health Network Cancer Institute, Division of Neuro Oncology, Pittsburgh, PA, USA

Glioblastoma (GBM) carries an abysmal prognosis. Current standard of care involves an aggressive multimodality approach including surgical resection followed by adjuvant chemoradiation. Despite this approach, overall survival remains poor and treatment approaches continue to evolve. Given the successes of immunotherapy in other disease sites, implementation in GBM management may improve outcomes. We conducted this retrospective National Cancer Database (NCDB) study to analyze treatment trends and outcomes from 2004-2015 regarding immunotherapy for GBM and queried for patients diagnosed between 2004-2015 with GBM and excluded patients treated without surgery, extracranial radiation, or chemotherapy as well as those lost to follow up.

Of the 39,317 eligible patients in this study, 511 were treated with immunotherapy and 38,806 lack thereof. Median overall survival for all patients was 15 months with a 2 and 5 year survival rate of 29% and 8%, respectively. Factors positively influencing delivery of immunotherapy included younger age, higher income, facility location in a metropolitan location, greater distance to the treatment facility, treatment at an academic facility, treatment outside of the years 2007 to 2009, and Caucasian race. On propensity matched analysis, survival was 18 months and 17 months with and without immunotherapy, respectively (p=0.15). Higher comorbidity, lower income, and male gender predicted for worse survival.

The results of the NCDB analysis showed an initial decrease and then increase in the use of immunotherapy in the management of GBM. Propensity-matched analyses did not show an overall survival benefit.

DOI: 10.29245/2578-3009/2019/2.1170 View / Download Pdf View Full Text
Click here for more articles

Special Features to Authors

Editing Services

We offer editing services to help you prepare a submission-ready manuscript.
Learn more

Article Outreach

The journal works hard to maximize the impact of published research.
Learn more

Reprints

Journal of Immunological Sciences offers a professional quality Reprint Service that enables users to have reprints delivered to their door at an affordable value.
Learn more